New cocktail of pain drugs aims to slash opioid use after major cancer surgery

NCT ID NCT04246697

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether a combination of gabapentin, ketorolac, and a nerve block, along with scheduled Tylenol, can reduce the need for opioid painkillers after head and neck cancer surgery involving free flap reconstruction. Half of the 30 participants will receive the standard approach (scheduled Tylenol plus opioids as needed), while the other half will receive the enhanced combination. Researchers will compare opioid use and pain scores between the two groups to see if the new regimen cuts opioid consumption by at least 30% while maintaining good pain control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Gabapentin, Ketorolac, Tylenol, Bupivacaine
What this could lead to
If successful, this approach could reduce reliance on opioids for pain control after major head and neck cancer surgery, potentially lowering side effects and addiction risk.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply broadly. The added drugs also carry their own risks, such as kidney injury or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANALGESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.